All relevant data are within the paper.

Introduction {#sec005}
============

Velopharyngeal closure between the oral and nasal cavities during speech is the most important function of the soft palate, to prevent the reflux of air and liquids into the nasopharynx during speech and swallowing, respectively. Velopharyngeal insufficiency (VPI), which is incomplete velopharyngeal closure, causes functional problems with speech including hypernasality, hyponasality, nasal turbulence, audible nasal emission, weak pressure consonants, and impaired speech intelligibility \[[@pone.0212752.ref001]\]. Some cleft palate patients exhibit VPI even after palatoplasty, thereby necessitating the use of several additional operation methods \[[@pone.0212752.ref002]--[@pone.0212752.ref003]\]. Traditionally, the velopharyngeal plasty using posterior pharyngeal wall flap is a standard operation method for VPI \[[@pone.0212752.ref004]--[@pone.0212752.ref006]\]; however, it is difficult to adapt this method for treatment in children, as it causes fundamental change to the velopharyngeal form, which may result in sleep apnea or an inability to perform nasal intubation during future orthodontic surgery \[[@pone.0212752.ref007]--[@pone.0212752.ref010]\].

Recently, several studies have reported that velopharyngeal structure augmentation methods, using implants or injectable materials, have served as alternatives to velopharyngeal plasty \[[@pone.0212752.ref011]--[@pone.0212752.ref023]\]. There are various artificial and biological materials that may serve in this capacity, including silicone, Teflon, porous polyethylene, Gore-Tex, calcium hydroxyapatite, auricular or costal cartilage, and autologous fat. The anatomic sites of implantation or injection also vary widely. Currently, surgeons perform augmentation based on their own empirically determined criteria as there are no standards for the use of a particular augmentation approach.

Among previous reports, only one study was an animal experimental trial; however, it merely served to investigate the histological fate of autogenous fat that was injected submucosally in the oropharyngeal region in rabbits \[[@pone.0212752.ref024]\]. Moreover, there have been no reports about optimal anatomic sites of implantation or injection.

In the present study, we experimentally investigated the optimal sites of velopharyngeal structure augmentation using saline injection in dogs. Dogs naturally exhibit VPI; thus, the rhinopharynx is not completely closed, even when the soft palate is lifted \[[@pone.0212752.ref025]\]. Previously, Kogo M et al. revealed that the levator veli palatini muscle (LVP), the principal muscle responsible for generating palatal movement, was active in expiration during hyperpnea occurring under rebreathing conditions \[[@pone.0212752.ref026]\]. Thus, we suspected that if velopharyngeal structure augmentation could lead to perfect velopharyngeal closure in dogs during rebreathing, this technique may be also useful for the treatment of patients with VPI.

Materials and methods {#sec006}
=====================

Velopharyngeal structure augmentations using saline injection were performed at the Large Animal Laboratory of the Graduate School of Dentistry of Osaka University, using 10 beagles (TOYO beagle; Oriental Yeast Co., Tokyo, Japan) aged 20--24 months and weighed 9--12 kg. All dogs were housed in separate cages and provided solid food (Oriental Yeast Co., Tokyo, Japan) and water ad libitum. All experimental protocols were reviewed and approved by the Intramural Animal Care and Use Committee of Osaka University Graduate School of Dentistry (approval number is 28-011-0).

All procedures were performed under general anesthesia administered by an intramuscular injection of medetomidine (0.02 mg/kg) and midazolam (0.3 mg/kg) followed by an intraperitoneal injection of sodium pentobarbital (25 mg/kg) 15 minutes after the intramuscular injection of anesthesia. Animals were fixed in the supine position after the ventilation tube was passed through the mouth, and all efforts were made to minimize suffering.

We exposed the LVP using an intraoral approach without damaging the muscles; subsequently, two bipolar platinum-iridium wire-hook electrodes (polar distance: 2 mm, diameter: 50 μm) were implanted into the bilateral LVP in the visible field, and electromyographic (EMG) activities of the muscles were recorded with a bioelectric amplifier (DAM-50; Nihon Koden Kogyo Co., Japan). EMGs of the LVP were recorded to check LVP movement during rebreathing. Next, 1 mL of saline containing 1/80,000 epinephrine was injected intraorally into the nasal mucosal side of the anterior two-thirds of the soft palate (n = 4), the posterior pharyngeal wall (n = 3), or the bilateral pharyngeal walls (n = 3); each injection was checked using an endoscope (i-Vets 8.0; SCETI K., Tokyo, Japan) ([Fig 1](#pone.0212752.g001){ref-type="fig"}). The inside end of the ventilation tube was withdrawn from the trachea to the oral cavity, to allow expiration through the nasal cavity. Then, the oral cavity was infilled with alginate impression material except for the electrode and the ventilation tube, to prevent oral air leak. While the dogs were under the rebreathing system, the amount of air leakage from the nasal cavity was measured by a flow meter (TSD117; BIOPAC Systems Inc., Japan) using the rubber tubes connected to the flow meter's sensor on the front of both nasal apertures ([Fig 2](#pone.0212752.g002){ref-type="fig"}). The outside of the rubber tubes was packed with quick self-curing acrylic resin (UNIFAST II; GC Co., Tokyo, Japan) to prevent air leakage. Data from the flow meter were recorded on a personal computer (U24a-px3210r Windows7; ASUSTek Computer Inc., Japan) using data acquisition and analysis software (Labchart7; AD Instruments, Japan) through a DC Amplifier (DA100C; BIOPAC Systems Inc., Japan), an Analog output module (HLT100-C; BIOPAC Systems Inc., Japan), and an AD converter (Power lab; AD Instruments Co., Tokyo, Japan).

![Injection sites around the velopharyngeal structure.](pone.0212752.g001){#pone.0212752.g001}

![Schematic diagram of the experimental model.](pone.0212752.g002){#pone.0212752.g002}

The rebreathing system is one of the ways to get the load breathing, which leads to the movement of LVP. The rebreathing system is a 1.5-L closed airway circuit constructed by connecting the intraoral tube to the bag valve mask. The level of partial pressure of carbon dioxide was increased by complete rebreathing, and it leads the activity of the LVP, which is one of the accessory respiratory muscles \[[@pone.0212752.ref026]\]. In our study, respiration was spontaneous without artificial ventilation.

Saline was injected in 1-mL increments, and the augmentation was performed in a step-by-step manner. Nasal air leakage was measured for each size of augmentation during rebreathing until complete velopharyngeal closure was achieved. Nasal air leakage was measured using the EMG of the LVP, from the baseline to the peak of the waveform ([Fig 3](#pone.0212752.g003){ref-type="fig"}).

![Measurement method of the amount of the nasal air leakage.](pone.0212752.g003){#pone.0212752.g003}

In addition, the increase rate of nasal resistance of expiration and inspiration was calculated when the saline was injected into the nasal mucosal site of the soft palate. The increase rate of nasal resistance was quantified with the following expression \[[@pone.0212752.ref027]\].

![](pone.0212752.e001.jpg){#pone.0212752.e001g}
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(R(x): nasal resistance when x mL saline was injected, F(x): nasal air flow per 1 sec when x mL saline was injected, V: respiratory pressure, N: constant)

Normality of the data were evaluated and due to their nonparametric nature, data were analyzed using the Kolmogorov-Smirnov test and Kruskal-Wallis test.

Results {#sec007}
=======

The median amount of nasal air leakage in the all dogs before the saline injection was 0.82 L/sec. The dogs injected with saline on the nasal mucosa side of the soft palates achieved steady augmentation, and nasal air leakage disappeared under rebreathing with 6 mL saline injection ([Table 1](#pone.0212752.t001){ref-type="table"}). Conversely, nasal air leakage remained in the dogs that underwent posterior pharyngeal wall injection even when saline was injected until the structural tensility reached its limit; this air leakage was nearly 35% of normal airflow (0.25 L/sec) after 6 mL saline injection. The dogs with saline injected in the bilateral pharyngeal walls did not show a steady decrease in air leakage. The injected saline leaked into the posterior pharyngeal cavity or the soft palate when the injection amount exceeded 4 mL and therefore, we did not inject a volume of more than 4 mL. In fact, the leakage from the bilateral pharyngeal walls increased by \>1 mL, relative to the injection volume. It appeared that the flat pharyngeal cavity was transmuted into a square-like shape following saline injection into the bilateral pharyngeal walls.

10.1371/journal.pone.0212752.t001

###### Relationship between median volume of nasal air leakage and volume of injected saline.

The interquartile ranges are shown in parentheses.

![](pone.0212752.t001){#pone.0212752.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                        The amount of nasal air leakage (L/s)   P-value\                                                                             
                                                                                (Prob\>ChiSq)                                                                        
  ------------------------------------- --------------------------------------- ------------------- ------------------- -------------------------------------------- -------
  The amount of injected saline (ml)\   **0**                                   0.84 (0.55--0.87)   0.75 (0.44--0.82)   0.64 (0.46--0.86)                            0.399

  1                                     0.52 (0.37--0.88)                       0.63 (0.35--0.68)   0.40 (0.31--0.50)   0.328                                        

  2                                     0.46 (0.30--0.74)                       0.63 (0.35--0.68)   0.52 (0.32--0.72)   0.904                                        

  3                                     0.27 (0.24--0.65)                       0.39 (0.35--0.54)   0.56 (0.38--0.88)   0.236                                        

  4                                     0.23 (0.15--0.27)                       0.35 (0.33--0.37)   0.56 (0.34--0.77)   0.030[\*](#t001fn001){ref-type="table-fn"}   

  5                                     0.15 (0.12--0.19)                       0.30 (0.30--0.35)                       0.034[\*](#t001fn001){ref-type="table-fn"}   

  6                                     0.00 (0.00--0.00)                       0.25 (0.20--0.26)                       0.019[\*](#t001fn001){ref-type="table-fn"}   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*p\<0.05

The results show the means of experimental values in three or four dogs.

Notably, the dogs with saline injected into the soft palate retained nasal air flow under normal breathing (at rest), even after undergoing maximum saline injection; moreover, inspiration under rebreathing was not prevented ([Fig 4](#pone.0212752.g004){ref-type="fig"}). The increase rate of nasal resistance was maximum at expiration depending on the volume of saline injection; however, the increase rate of nasal resistance at inspiration did not vary much with the volume of saline injection ([Table 2](#pone.0212752.t002){ref-type="table"}).

![Nasal air flow with 6 mL saline injection to the soft palate.](pone.0212752.g004){#pone.0212752.g004}

10.1371/journal.pone.0212752.t002

###### The median increase rate of nasal resistance by saline injection to the soft palate.

The interquartile ranges are shown in parentheses.
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  -----------------------------------------------------------------------------------------------------------------------------------------------
                                        Increase rate of nasal resistance   P-value\                                                         
                                                                            (Prob\>ChiSq)                                                    
  ------------------------------------- ----------------------------------- ------------------- -------------------------------------------- ----
  The amount of injected saline (ml)\   0                                   0.00 (0.00--0.00)   0.00 (0.00--0.00)                            \-

  1                                     0.50 (0.03--0.69)                   0.33 (0.10--1.32)   0.734                                        

  2                                     0.81 (0.19--0.96)                   0.59 (0.49--1.52)   0.865                                        

  3                                     1.43 (0.27--2.49)                   0.37 (0.23--2.97)   0.807                                        

  4                                     2.64 (2.06--2.85)                   1.06 (0.83--1.45)   0.011[\*](#t002fn001){ref-type="table-fn"}   

  5                                     3.68 (3.23--5.01)                   1.18 (1.05--1.63)   0.007[\*](#t002fn001){ref-type="table-fn"}   

  6                                                                         1.28 (1.24--1.98)   \-                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------

\*p\<0.05

Discussion {#sec008}
==========

In this study, we investigated velopharyngeal structure augmentation in dogs, as they demonstrate similar velopharyngeal physiological properties to humans, especially in terms of respiration patterns \[[@pone.0212752.ref024]\].

It is well known that the structure of the pharynx in humans is different from that in many animals. The pharynx of the humans is right-angled, and the epiglottis does not touch the velum whereas the pharynx of animals is straight, and the velum and the epiglottis can touch each other during breathing at rest. However, humans breathe exclusively through the nose at rest; during physical exercise, the breathing route is switched from nasal to oronasal in a manner that is also present in monkeys and dogs, and for this reason, we selected dogs as the experimental animals \[[@pone.0212752.ref028],[@pone.0212752.ref029]\]. Many other animals breathe entirely through the nose. In humans, monkeys, and dogs, when hyperpnea is produced by the rebreathing technique, the LVP is active during the expiratory phase but inactive during the inspiratory phase, and this results in oronasal breathing \[[@pone.0212752.ref026],[@pone.0212752.ref030]--[@pone.0212752.ref032]\]. In our study, this phenomenon was also observed; furthermore, the nasal air leakage increased during inspiration and decreased during expiration.

VPI occurs in 20--30% of patients after palatoplasty due to the shortfall of the original soft palate, scarring of the soft palate after palatoplasty, lack of movement of the LVP (important in lifting the soft palate), or paralysis of the LVP \[[@pone.0212752.ref001]\]. However, if VPI is successfully treated by speech therapy, a suitable bulb-attached palatal lift prosthesis (Bulb-PLP), and a velopharyngeal plasty, following correct diagnosis and linguistic evaluation, this condition could be substantially improved in many cases \[[@pone.0212752.ref001]\].

Velopharyngeal structure augmentation methods are used as a helpful alternative to velopharyngeal plasty, but these methods remain to be outside of the standard treatment approaches. Bishop A et al. reviewed reports of several past investigations on autologous fat grafting for the treatment of VPI; three of these reported grafting to the posterior pharyngeal wall, and eight of these reported simultaneous grafting to three regions: soft palate, posterior pharyngeal wall, and bilateral pharyngeal walls \[[@pone.0212752.ref021]\]. Importantly, questions remained regarding the optimal graft volume and injection sites. Recently, only one report discussed augmentation that was limited to the soft palate \[[@pone.0212752.ref023]\]. Furthermore, many reports on velopharyngeal augmentation have found that this treatment did not improve hypernasality in some VPI patients \[[@pone.0212752.ref013],[@pone.0212752.ref015],[@pone.0212752.ref018],[@pone.0212752.ref019],[@pone.0212752.ref021],[@pone.0212752.ref023]\].

Our study evaluated the optimal injection sites for improvement of VPI, and we found that saline injection to the nasal mucosa of the soft palate is most effective in dogs. The advantage of our method is that it allows an adjustment of the injection volume corresponding to the level of nasal air leakage. To our knowledge, this study is the first short-term experiment to use saline and therefore, we cannot easily compare our results to those of previous studies. Further studies must include long-term evaluations of several materials such as autologous fat, costal cartilage, and silicone because saline is easy to absorb, and it is only a temporary filler.

During velopharyngeal plasty, the nasal resistance increased, and airway narrowing had occurred. However, the nasal resistance to the injection to the nasal mucosal side of the soft palate was not significantly increased during inspiration in contrast to that during expiration. It was considered that it was due to an increase in the tension of the mucous membrane by the injection, and it prevented the movement of the membrane during inspiration. Thus, injection to the soft palate is considered to have more advantages than velopharyngeal plasty.

Human and dog velopharyngeal structures are quite different whereas they may function similarly during respiration; we must re-evaluate the amount of injection when applying our results to human patients. Moreover, we cannot experimentally evaluate speech in dogs. Another limitation of our study is the small sample size. VPI does not vary widely across groups of normal dogs whereas the VPI in humans exhibits considerable individual variability resulting from various prior treatments and/or age-related changes. Finally, growth is an important factor. If the treatment for VPI is performed during childhood, VPI can reoccur after growth because velopharyngeal space will become wider. As a practical proposition, the ideal injection volume for a patient with VPI may be determined by lateral cephalic radiography, computed tomography, magnetic resonance imaging, or endoscopy. Lau D et al. assessed each patient individually via nasoendoscopy to determine the amount of fat to be grafted; in that study, approximately 1 mL of the fat graft was used for every 0.1 cm^2^ of VPI \[[@pone.0212752.ref020]\]. An alternate method to determine the amount of injection may include gradual injection while assessing speech, performed under local anesthesia.

Our study results clearly demonstrate that the augmentation of the nasal mucosa of the soft palate assists in the management of air leakage in dogs. Although it is unclear how extensively these findings will influence the treatment of patients with VPI, our present results certainly warrant additional examination.
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